Vertex Pharmaceuticals Incorporated (VRTX)

$397.48

-0.22

(-0.06%)▲

Market is closed - opens 7 PM, 29 Apr 2024
star icon

Vertex Pharmaceuticals Incorporated is a biotechnology company that develops and commercializes treatments for cystic fibrosis and other serious medical conditions.

Insights on Vertex Pharmaceuticals Incorporated

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 2.48B → 2.51B (in $), with an average increase of 1.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 1.03B → 968.8M (in $), with an average decrease of 6.4% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 51.5% return, outperforming this stock by 34.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 241.4% return, outperforming this stock by 156.9%

Performance

  • $393.76
    $399.68
    $397.48
    downward going graph

    0.94%

    Downside

    Day's Volatility :1.48%

    Upside

    0.55%

    downward going graph
  • $320.01
    $448.40
    $397.48
    downward going graph

    19.49%

    Downside

    52 Weeks Volatility :28.63%

    Upside

    11.36%

    downward going graph

Returns

PeriodVertex Pharmaceuticals IncorporatedSector (Health Care)Index (NASDAQ Composite)
3 Months
-7.55%
0.5%
3.1%
6 Months
11.94%
13.6%
26.0%
1 Year
17.19%
5.7%
31.2%
3 Years
84.52%
14.2%
13.0%

Highlights

Market Capitalization
103.6B
Book Value
$68.22
Earnings Per Share (EPS)
13.91
PE Ratio
28.81
PEG Ratio
0.53
Wall Street Target Price
466.14
Profit Margin
36.68%
Operating Margin TTM
37.97%
Return On Assets TTM
13.17%
Return On Equity TTM
22.99%
Revenue TTM
9.9B
Revenue Per Share TTM
38.3
Quarterly Revenue Growth YOY
9.3%
Gross Profit TTM
5.3B
EBITDA
4.5B
Diluted Eps TTM
13.91
Quarterly Earnings Growth YOY
0.18
EPS Estimate Current Year
16.75
EPS Estimate Next Year
18.21
EPS Estimate Current Quarter
4.1
EPS Estimate Next Quarter
4.1

Analyst Recommendation

Buy
    72%Buy
    27%Hold
    0
    0%Sell
Based on 37 Wall street analysts offering stock ratings for Vertex Pharmaceuticals Incorporated(by analysts ranked 0 to 5 stars)
Based on 37 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
27
26
26
Hold
10
10
11
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 17.27%

Current $397.48
Target $466.14

Company Financials

FY18Y/Y Change
Revenue
3.0B
↑ 22.46%
Net Income
2.1B
↑ 695.83%
Net Profit Margin
68.8%
↑ 58.21%
FY19Y/Y Change
Revenue
4.2B
↑ 36.59%
Net Income
1.2B
↓ 43.88%
Net Profit Margin
28.27%
↓ 40.53%
FY20Y/Y Change
Revenue
6.2B
↑ 49.07%
Net Income
2.7B
↑ 130.43%
Net Profit Margin
43.7%
↑ 15.43%
FY21Y/Y Change
Revenue
7.6B
↑ 22.06%
Net Income
2.3B
↓ 13.63%
Net Profit Margin
30.92%
↓ 12.78%
FY22Y/Y Change
Revenue
8.9B
↑ 17.91%
Net Income
3.3B
↑ 41.84%
Net Profit Margin
37.2%
↑ 6.28%
FY23Y/Y Change
Revenue
9.8B
↑ 10.17%
Net Income
3.6B
↑ 8.96%
Net Profit Margin
36.79%
↓ 0.41%
Q3 FY22Q/Q Change
Revenue
2.3B
↑ 6.29%
Net Income
930.5M
↑ 14.81%
Net Profit Margin
39.86%
↑ 2.96%
Q4 FY22Q/Q Change
Revenue
2.3B
↓ 1.35%
Net Income
818.9M
↓ 11.99%
Net Profit Margin
35.56%
↓ 4.3%
Q1 FY23Q/Q Change
Revenue
2.4B
↑ 3.13%
Net Income
699.8M
↓ 14.54%
Net Profit Margin
29.47%
↓ 6.09%
Q2 FY23Q/Q Change
Revenue
2.5B
↑ 4.99%
Net Income
915.7M
↑ 30.85%
Net Profit Margin
36.73%
↑ 7.26%
Q3 FY23Q/Q Change
Revenue
2.5B
↓ 0.39%
Net Income
1.0B
↑ 13.06%
Net Profit Margin
41.69%
↑ 4.96%
Q4 FY23Q/Q Change
Revenue
2.5B
↑ 1.38%
Net Income
968.8M
↓ 6.42%
Net Profit Margin
38.48%
↓ 3.21%
FY18Y/Y Change
Total Assets
6.2B
↑ 76.14%
Total Liabilities
1.8B
↑ 20.42%
FY19Y/Y Change
Total Assets
8.3B
↑ 33.18%
Total Liabilities
2.2B
↑ 23.34%
FY20Y/Y Change
Total Assets
11.8B
↑ 41.27%
Total Liabilities
3.1B
↑ 37.25%
FY21Y/Y Change
Total Assets
13.4B
↑ 14.3%
Total Liabilities
3.3B
↑ 8.73%
FY22Y/Y Change
Total Assets
18.2B
↑ 35.13%
Total Liabilities
4.2B
↑ 27.18%
FY23Y/Y Change
Total Assets
22.7B
↑ 25.23%
Total Liabilities
5.1B
↑ 21.51%
Q3 FY22Q/Q Change
Total Assets
16.7B
↑ 7.21%
Total Liabilities
3.7B
↑ 0.77%
Q4 FY22Q/Q Change
Total Assets
18.2B
↑ 8.65%
Total Liabilities
4.2B
↑ 15.27%
Q1 FY23Q/Q Change
Total Assets
19.0B
↑ 4.54%
Total Liabilities
4.5B
↑ 7.17%
Q2 FY23Q/Q Change
Total Assets
20.3B
↑ 7.25%
Total Liabilities
4.9B
↑ 7.42%
Q3 FY23Q/Q Change
Total Assets
21.7B
↑ 6.77%
Total Liabilities
5.2B
↑ 6.85%
Q4 FY23Q/Q Change
Total Assets
22.7B
↑ 4.62%
Total Liabilities
5.1B
↓ 1.22%
FY18Y/Y Change
Operating Cash Flow
1.3B
↑ 50.34%
Investing Cash Flow
-202.2M
↓ 53.81%
Financing Cash Flow
-71.2M
↓ 204.12%
FY19Y/Y Change
Operating Cash Flow
1.6B
↑ 23.54%
Investing Cash Flow
-1.2B
↑ 511.07%
Financing Cash Flow
126.8M
↓ 278.0%
FY20Y/Y Change
Operating Cash Flow
3.3B
↑ 107.32%
Investing Cash Flow
99.4M
↓ 108.05%
Financing Cash Flow
-505.3M
↓ 498.57%
FY21Y/Y Change
Operating Cash Flow
2.6B
↓ 18.75%
Investing Cash Flow
-340.9M
↓ 443.0%
Financing Cash Flow
-1.5B
↑ 192.51%
FY22Y/Y Change
Operating Cash Flow
4.1B
↑ 56.23%
Investing Cash Flow
-321.1M
↓ 5.81%
Financing Cash Flow
-67.7M
↓ 95.42%
Q3 FY22Q/Q Change
Operating Cash Flow
955.5M
↓ 16.17%
Investing Cash Flow
-384.2M
↑ 524.72%
Financing Cash Flow
-60.2M
↓ 226.21%
Q4 FY22Q/Q Change
Operating Cash Flow
1.1B
↑ 12.86%
Investing Cash Flow
175.6M
↓ 145.71%
Financing Cash Flow
40.2M
↓ 166.78%
Q1 FY23Q/Q Change
Operating Cash Flow
899.9M
↓ 16.55%
Investing Cash Flow
-1.8B
↓ 1144.19%
Financing Cash Flow
-294.7M
↓ 833.08%
Q2 FY23Q/Q Change
Operating Cash Flow
1.1B
↑ 26.06%
Investing Cash Flow
-303.9M
↓ 83.43%
Financing Cash Flow
17.3M
↓ 105.87%

Technicals Summary

Sell

Neutral

Buy

Vertex Pharmaceuticals Incorporated is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.7%
11.94%
17.19%
84.52%
130.52%
Moderna, Inc.
Moderna, Inc.
-3.99%
47.66%
-18.37%
-42.11%
322.35%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-8.6%
12.46%
11.47%
77.72%
156.63%
Novo Nordisk A/s
Novo Nordisk A/s
-2.8%
32.13%
52.48%
239.51%
414.16%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.81
28.81
0.53
16.75
0.23
0.13
NA
68.22
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.04
26.04
1.46
45.0
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
47.43
47.43
2.4
3.35
0.88
0.23
0.01
23.9
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.6B
130.52%
28.81
36.68%
Moderna, Inc.
Moderna, Inc.
Buy
$41.7B
322.35%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.5B
156.63%
26.04
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$562.8B
414.16%
47.43
36.03%

Institutional Holdings

  • Vanguard Group Inc

    8.62%

  • BlackRock Inc

    8.47%

  • Capital World Investors

    8.44%

  • FMR Inc

    5.02%

  • State Street Corporation

    4.68%

  • AllianceBernstein L.P.

    2.72%

Company Information

Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.

Organization
Vertex Pharmaceuticals Incorporated
Employees
5400
CEO
Dr. Jeffrey Marc Leiden M.D., Ph.D.
Industry
Health Technology

Discover More

FAQs